Possibility to Treat Lung Tuberculosis without Use of Rifampicin in Heart Transplant Recipients – Two Cases Report
Dariusz Jastrzebski, Michal Zakliczynski, Jerzy Kozielski, Miroslawa Siola, Szymon Dworniczak, Agnieszka Wojdyla, Marian Zembala
Ann Transplant 2003; 8(1): 42-44
ID: 496881
Available online:
Published: 2003-03-14
Pulmonary infections remain the leading cause of death in patients after heart transplantation. Lung tuberculosis is more common in transplant recipients than in general population. Two cases of tuberculosis are presented in patients after heart transplantation. Regarding to influence of rifampicin on immunosuppressive therapy, those patients were treated with antimycobacterial drugs except rifampicin. A cure without recurrence can be achieved with a scheme of treatment regimes without rifampicin.
Keywords: Heart Transplantation, Lung Tuberculosis Treatment
